Visit our MS learning channel on YouTube, which provides hundreds of MS educational videospresented by MS Experts from across the USA. Archived here: www.youtube.com/msviewsandnews-- Also please visit our Social media platforms: Facebook, Twitter, and Instagram . Each providingimportant information for the MS community. Furthermore, scroll down the left side of this blog to learn from the resources and links.

Disclaimer:'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, for your personal knowledge and to keep you informed of current health-related issues. It is not a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

Tuesday, April 20, 2010

Early Line Dominance of Teva's Copaxone and Biogen Idec's Avonex in the Treatment of Multiple Sclerosis

Early Line Dominance of Teva's Copaxone and Biogen Idec's Avonex in the Treatment of Multiple Sclerosis To Diminish Following the Launch of Oral Disease-Modifying Therapies

WALTHAM, Mass., April 19/PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that early lines of therapy for the treatment of multiple sclerosis are dominated by Teva's Copaxone and Biogen Idec's Avonex, an interferon-beta (IFN-beta) agent. According to surveyed neurologists, Copaxone's superior side-effect profile, particularly the lack of flu-like symptoms, is a key driver of its first-line use. For Avonex, lower frequency of injection-site reactions and weekly dosing are advantages surveyed neurologists say are driving its early line use. However, the new report entitled Treatment Algorithms in Multiple Sclerosis also finds that some use of these agents will shift to later lines of therapy following the anticipated launch of oral disease-modifying therapies for the treatment of multiple sclerosis.

According to the report, 48 and 43 percent of surveyed neurologists expect to decrease their first-line use of Copaxone and Avonex, respectively, by 2012, while 45 and 38 percent of respondents expect to increase their third-line use of each respective therapy. Meanwhile, approximately half of surveyed neurologists do not expect to adjust their prescribing of Copaxone, Avonex or any other IFN-beta therapies in any line of treatment over the next two years.

"While the launch of the first oral disease-modifying therapies will no doubt be a transformative event in the treatment landscape for multiple sclerosis, many surveyed neurologists say they do not expect to change their prescribing habits over the next two years, which demonstrates how entrenched Copaxone, Avonex and the otherIFN-beta therapies are in the treatment algorithm for multiple sclerosis," said Decision Resources Therapeutic Area Director Bethany Kiernan, Ph.D. "The fact that the prescribing trend is similar for Copaxone and all of the IFN-beta agents suggests there is little differentiation in the minds of neurologists in the suitability of these agents for use in early lines of therapy, making it critical for product marketers to emphasize the advantages their product offers to capture and defend market share."

SYMPTOMS of MS

In multiple sclerosis , damage to the myelin in the central nervous system (CNS), and to the nerve fibers themselves, interferes with the transmission of nerve signals between the brain and spinal cord and other parts of the body. This disruption of nerve signals produces the primary symptoms of MS, which vary depending on where the damage has occurred.

Over the course of the disease, some symptoms will come and go, while others may be more lasting.

MS Views and News Guide Star Status

Find MS Views on Facebook

About This Blog

A web-blog (formerly known as Stu's Views and MS News), now published by MS Views and News, a patient advocacy organization. The information on this blog helps to Empower those affected by Multiple Sclerosis globally, with education, information, news and community resources.

MS Coalition Associate Member

MS Views and News

Healing the Soul, by B. Khatri, MD

Click photo for more detail

Sharecare Marketing - March 2014 - LISTED Stuart among the Top "10"

Social HealthMakers: Multiple Sclerosis

Disclaimer:

"Stu's Views & MS News" / 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly

About Me

MS Views and News is a 501c3 Not-for-Profit organization that provides IMPACTFUL information to the MS (Multiple Sclerosis) community. To learn of the educational programs we provide live and virtually, opt-in with us from here: www.register.msviewsandnews.org
- thank you -

2014 MS Symposium from Miami, Fl

Brian Steingo, MD - Presents on Dietary & Self Aspects

MS Views and News

MS Views and News (MSVN), is dedicated to the global collection and distribution of information concerning Multiple Sclerosis (MS). Through partnering relationships, MSVN provides education, advocacy and service to empower and enhance the quality of life of the MS community.

Marketing Opportunities with MS Views and News

Att: Marketers :

Get New Exposure to either venues in Florida, the USA or Globally

Becoming a Sponsor of MS Views and News will enable us a few dollars more to host Multiple Sclerosis learning programs for those affected by MS and a sponsorship at the correct tier would place your logo and url on our site(s) and possibly with our social media offering you lots of new exposure.

FL Dept of Agriculture

MS Views and News, Inc. is registered with the Florida Department of Agriculture and Consumer Services, Registration # CH37993

A COPY OF THE OFFICIAL REGISTRATION AND FINANCIAL INFORMATION MAY BE OBTAINED FROM THE DIVISION OF CONSUMER SERVICES BY CALLING TOLL-FREE (800-435-7352) WITHIN THE STATE. REGISTRATION DOES NOT IMPLY ENDORSEMENT, APPROVAL, OR RECOMMENDATION BY THE STATE.